Expand TAK Menu
TAK MENU

TAK Latest Press Releases

-- June 24, 2026 --

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO Business Wire 3:05 AM

-- June 23, 2026 --

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations PRNewswire 8:00 AM

-- June 15, 2026 --

New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 Business Wire 12:00 PM

-- June 11, 2026 --

Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Business Wire 7:00 AM

-- June 9, 2026 --

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease Business Wire 4:30 PM

-- May 18, 2026 --

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda Business Wire 5:51 PM

-- May 13, 2026 --

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results Business Wire 2:38 AM

-- May 4, 2026 --

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) Business Wire 8:00 AM

-- March 28, 2026 --

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care Business Wire 3:00 PM

-- March 2, 2026 --

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera Business Wire 2:00 AM

-- February 19, 2026 --

Positive Phase 3 Data Demonstrate Potential for ENTYVIO (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis Business Wire 12:00 PM

-- February 10, 2026 --

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 Business Wire 3:15 AM
Market Data Delayed 15 Minutes